公开(公告)号：US20230017956A1

公开(公告)日：2023-01-19

申请号：US17900527

申请日：2022-08-31

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

发明人： Kyungho CHOI ,  Hyung-Bae Park ,  Ji Eun Lee ,  Yumi Oh ,  Ki-Hyun Kim ,  Soohyun Kim ,  Hyori Kim ,  Junho Chung

IPC分类号： A61K47/68 ,  A61K35/17 ,  C12N15/85 ,  A61K39/395 ,  A61K38/17 ,  C07K16/16 ,  C07K16/28

摘要： A chimeric antibody receptors with anti-cotinine antibodies linked, and uses thereof are disclosed. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

公开(公告)号：US20180256744A1

公开(公告)日：2018-09-13

申请号：US15753212

申请日：2016-08-17

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

发明人： Kyungho CHOI ,  Hyung-Bae PARK ,  Ji Eun LEE ,  Yumi OH ,  Ki-Hyun KIM ,  Soohyun KIM ,  Hyori KIM ,  Junho CHUNG

IPC分类号： A61K47/68 ,  C07K16/16 ,  A61K35/17 ,  C12N15/85 ,  A61K39/395 ,  C07K16/28

CPC分类号： A61K47/6819 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  A61K39/39558 ,  A61P35/00 ,  C07K16/16 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/10 ,  C12N15/85

摘要： The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.